High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma

Value of F-18 Fluorodeoxyglucose Positron Emission Tomography for Predicting the Clinical Outcome of Patients With Aggressive Lymphoma Prior to and After Autologous Stem-Cell Transplantation*

“…These patients may also benefit from ASCT. [5][6][7] The success rate of ASCT depends on a number of factors. 8 These include age, concurrent medical conditions, the Karnofsky global performance status, the histologic type of lymphoma, and the number of extranodal disease sites.…”

Value of F-18 Fluorodeoxyglucose Positron Emission Tomography for Predicting the Clinical Outcome of Patients With Aggressive Lymphoma Prior to and After Autologous Stem-Cell Transplantation*

“…These patients may also benefit from ASCT. [5][6][7] The success rate of ASCT depends on a number of factors. 8 These include age, concurrent medical conditions, the Karnofsky global performance status, the histologic type of lymphoma, and the number of extranodal disease sites.…”

Allogeneic and autologous bone marrow transplantation for acute leukemia and malignant lymphoma: Current status

“…Conventional salvage therapy for patients with non-Hodgkin's lymphoma (NHL) after first relapse is unsuccessful in the majority of cases (Singer and Goldstone, 1986). For this reason, marrow transplantation has been performed in patients after failure of conventional chemotherapy Philip et al, 1985;Armitage et al, 1986;Goldstone, 1986). Phase of disease and responsiveness of the tumour to chemotherapy at the time of transplant appear to be the best predictors for long-term disease-free survival.…”

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation

“…BCNU (bis-chloroethylnitrosourea or carmustine) is an alkylating agent that has been successfully used in combination with alkylating agents in conditioning regimens for the treatment of lymphomas and multiple myeloma [3][4][5] and in the treatment of brain tumors [6]. BCNU is a lipophilic substance, which cross the blood-brain barrier and produces a prolonged and cumulative myelosuppression [7].…”

Value of F-18 Fluorodeoxyglucose Positron Emission Tomography for Predicting the Clinical Outcome of Patients With Aggressive Lymphoma Prior to and After Autologous Stem-Cell Transplantation*

“…These patients may also benefit from ASCT. [5][6][7] The success rate of ASCT depends on a number of factors. 8 These include age, concurrent medical conditions, the Karnofsky global performance status, the histologic type of lymphoma, and the number of extranodal disease sites.…”

Allogeneic and autologous bone marrow transplantation for acute leukemia and malignant lymphoma: Current status

“…Conventional salvage therapy for patients with non-Hodgkin's lymphoma (NHL) after first relapse is unsuccessful in the majority of cases (Singer and Goldstone, 1986). For this reason, marrow transplantation has been performed in patients after failure of conventional chemotherapy Philip et al, 1985;Armitage et al, 1986;Goldstone, 1986). Phase of disease and responsiveness of the tumour to chemotherapy at the time of transplant appear to be the best predictors for long-term disease-free survival.…”

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation

“…BCNU (bis-chloroethylnitrosourea or carmustine) is an alkylating agent that has been successfully used in combination with alkylating agents in conditioning regimens for the treatment of lymphomas and multiple myeloma [3][4][5] and in the treatment of brain tumors [6]. BCNU is a lipophilic substance, which cross the blood-brain barrier and produces a prolonged and cumulative myelosuppression [7].…”

Value of F-18 Fluorodeoxyglucose Positron Emission Tomography for Predicting the Clinical Outcome of Patients With Aggressive Lymphoma Prior to and After Autologous Stem-Cell Transplantation*

“…These patients may also benefit from ASCT. [5][6][7] The success rate of ASCT depends on a number of factors. 8 These include age, concurrent medical conditions, the Karnofsky global performance status, the histologic type of lymphoma, and the number of extranodal disease sites.…”

Allogeneic and autologous bone marrow transplantation for acute leukemia and malignant lymphoma: Current status

“…Conventional salvage therapy for patients with non-Hodgkin's lymphoma (NHL) after first relapse is unsuccessful in the majority of cases (Singer and Goldstone, 1986). For this reason, marrow transplantation has been performed in patients after failure of conventional chemotherapy Philip et al, 1985;Armitage et al, 1986;Goldstone, 1986). Phase of disease and responsiveness of the tumour to chemotherapy at the time of transplant appear to be the best predictors for long-term disease-free survival.…”

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation

“…BCNU (bis-chloroethylnitrosourea or carmustine) is an alkylating agent that has been successfully used in combination with alkylating agents in conditioning regimens for the treatment of lymphomas and multiple myeloma [3][4][5] and in the treatment of brain tumors [6]. BCNU is a lipophilic substance, which cross the blood-brain barrier and produces a prolonged and cumulative myelosuppression [7].…”